Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CCMC: Children ages 7-22 years (inclusive) with documented sickle cell disease~* UCHC: Adults 18 years (inclusive) and above with documented sickle cell disease~* Sudden onset of acute pain consistent with a vasoocclusive episode -Pain requiring hospitalization, placement on pain protocol, and patient- controlled opiates~* Pain score of greater than or equal to 5 out of 10 when ketamine infusion is started~* Cognitive ability to report pain on a 0 to 10 Numerical Rating Scale (NRS)~* At least one prior hospitalization for vasoocclusive pain at CCMC in the previous 24 months~* Parental consent and child assent~Exclusion Criteria:~* Children hospitalized for a primary diagnosis other than vasoocclusive episode~* Concurrent Acute Chest Syndrome (ACS)~* Hemoglobin \< 5 mg/dL~* Concurrent history of glaucoma or raised intracranial pressure~* Signs or symptoms consistent with stroke~* History of liver or renal dysfunction~* Pregnancy (females age 12 and above must have pregnancy test)~* Simultaneous participation in investigational drug study~* Primary language spoken other than English~* No hospitalizations to CCMC for vasoocclusive pain in the previous 24 months

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): This group will receive ketamine

Based on this trial design, predict the completion outcome and termination type (if applicable).